AstraZeneca seeking to break 100 billion won barrier with Atacand and Crestor

AstraZeneca said on January 5 its employees are rolling up its sleeves to boost sales of Atacand and Crestor up to a 100 billion-won level this year, consolidating its firmer presence in the cardiovascular sector.

The benefits of Atacand in hypertension are well documented from several trials comparing Atacand with placebo, other angiotensin receptor blockers (such as losartan) and other ant...